tbuckley/cabot-search huggingface dataset:
Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe
Authors: Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Yasuhiro Sone, Yuji Kaneoka, Atsuyuki Maeda, Yasunori Minami, Masatoshi Kudo, Abby B. Siegel, Anthony B. El-Khoueiry, Richard S. Finn, Katherine A. Guthrie, Abhishek Goyal, Alan P. Venook, Charles D. Blanke, Elizabeth C. Verna, Lorna Dove, Jean Emond, Tomoaki Kato, Benjamin Samstein, Ronald Busuttil, Helen Remotti, Amy Coffey, Robert S. Brown Jr, Chiun Hsu, Bang-Bin Chen, Chien-Hung Chen, Ming-Chih Ho, Jason Chia-Hsien Cheng, Norihiro Kokudo, Takamichi Murakami, Winnie Yeo, Jinsil Seong, Ji-Dong Jia, Kwan-Hyub Han, Ann-Lii Cheng
Journal: Liver Cancer (2015)
HIGH NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS PREDICT ENHANCED PERIPROCEDURAL INFLAMMATORY RESPONSE FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN STABLE ISCHEMIC HEART DISEASE PATIENTS
Authors: Carlos V. Serrano, Fabiana Rached, Fabio S. Brito, Marcelo Katz, Cibele Garzillo, Antonio Pesaro, Teresa C.D.C. Nascimento, Michael E. Farkouh, Marco A. Perin, Roberto Kalil-Filho
Journal: Journal of the American College of Cardiology (2017)
CHANGES IN CITRIC ACID METABOLISM ARE ASSOCIATED WITH THE DEVELOPMENT OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN MICE AND IN PATIENTS
Authors: Aarti Asnani, Xu Shi, Laurie Farrell, Robert Tainsh, Sara Vandenwijngaert, Kai-Hung Cheng, Emmanuel Buys, Robert Gerszten, Marielle Scherrer-Crosbie
Journal: Journal of the American College of Cardiology (2017)
Molecular classification of ampullary adenocarcinoma: Comparative prognostic performance of the 92-gene assay versus histomolecular analysis.
Authors: Aaron Schueneman, Huamin Wang, Harris S Soifer, Catherine A. Schnabel, Robert A. Wolff, Gauri R. Varadhachary, Michael J. Overman
Journal: Journal of Clinical Oncology (2014)

4141 Background: As distinct epithelia coalesce within the ampulla (duodenal, pancreatic, and biliary), the exact epithelial origin of ampullary carcinomas remains unclear and in part contributes to the clinical heterogeneity for these cancers. Differential expression of CDX2 and MUC1 along with histological subtype [intestinal (INT), pancreaticobiliary (PB), and mixed] have been used to subclassify ampullary tumors by histomolecular phenotype (Chang et al. JCO 2013). We compared the ability of a 92-gene RT-PCR Assay (CancerTYPE ID, bioTheranostics. Inc.) and histomolecular phenotype to prognostically stratify ampullary adenocarcinomas. Methods: In this prospectively-defined, blinded study, ampullary adenocarcinoma samples (N=77) were evaluated by the 92-gene assay and histomolecular phenotype. A total of 54 ampullary adenocarcinomas were compared after the exclusion of 23 samples that failed QC. A reference diagnosis was established by independent histopathological review prior to sample blinding. Relapse-free survival (RFS) and overall survival (OS) for patients were evaluated by Kaplan-Meier analysis with log-rank P-values. Results: For tumor subtyping, the sensitivity of the 92-gene assay and histomolecular classification were similar for the intestinal subtype, however the 92-gene assay demonstrated higher sensitivity for the Pb subtype (P=0.045). While the 92-gene assay was prognostic for both RFS (HR=2.81, P=0.02) and OS (HR=2.49, median OS 114 m vs. 36.4 m, P=0.03), histomolecular classification failed to demonstrate a significant difference in RFS (HR = 1.02, P=0.96) or OS (HR=1.07, P=0.87). Stratification of the cohort to include lymph node status revealed three distinct prognostic groups for ampullary subtypes predicted by the 92-gene Assay (P=0.04), but not for histomolecular phenotype (P=0.39). Conclusions: Molecular classification of ampullary adenocarcinomas into intestinal and pancreaticobiliary subtypes is prognostically relevant and may have therapeutic implications. Further validation of this novel 92-gene assay in comparison to histomolecular phenotype in a larger ampullary adenocarcinoma dataset is needed.
Donor Lymphocytes Stimulated with CMV pp65 Gene Modified Dendritic Cells for Prophylaxis of CMV Following Allogeneic Haemopoietic Stem Cell Transplantation.
Authors: Kenneth P. Micklethwaite, Leighton E. Clancy, Upinder Sandher, Elizabeth Snape, Kenneth Francis Bradstock, David J. Gottlieb
Journal: Blood (2007)
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.
Authors: Dario Neri, Benjamin Weide, Thomas K. Eigentler, Annette Pflugfelder, Henning Zelba, Graham P. Pawelec, Leonardo Giovannoni, Pier Adelchi Ruffini, Giuliano Elia, Ralf Gutzmer, Jürgen C. Becker, Claus Garbe
Journal: Journal of Clinical Oncology (2014)

9041^ Background: In previous studies, intralesional injection with interleukin-2 (IL2) showed efficacy for the intratumoral treatment of cutaneous/subcutaneous metastases in advanced melanoma patients. Objectives of this multicenter study (ClinicalTrials.gov Id.: NCT01253096) were to investigate whether intralesional delivery of L19-IL2, a targeted form of IL2, would yield similar results with reduced injection frequency and treatment duration and whether systemic immune responses were induced by the local treatment. L19-IL2 is a recombinant fusion protein, consisting of IL2 fused to a single-chain monoclonal antibody (L19) directed against extradomain B of fibronectin, a well-characterized marker of angiogenesis. Methods: Twenty-five patients with unresectable Stage IIIB/IIIC melanoma and cutaneous/subcutaneous injectable metastases received intratumoral injections of L19-IL2 once per week at a maximum daily dose of 10 MIU for 4 consecutive weeks. Tumor response was evaluated twelve weeks after the first treatment. Results: Twenty-four of 25 enrolled patients were evaluable. Toxicities were mild and comparable to that of free IL2. No serious adverse event was recorded. A complete response of all metastases was achieved in 6 patients (25%), which was long-lasting in most cases (5 patients ≥ 24 months). Analysis of progression rates for these patients seems to show an effect of intratumoral injection of L19-IL2 in retarding spread of the disease to distant lymph nodes or appearance of visceral metastases, as compared to historical controls. A significant temporary increase of peripheral regulatory T cells and a sustained decrease of myeloid-derived suppressor cells was observed upon treatment. Conclusions: Intratumoral L19-IL2 treatment elicited objective responses in a high percentage of lesions. The targeted form of IL2 yielded results similar to those of the untargeted cytokine, but at lower cumulative doses and more favorable schedule and treatment duration. Analysis of progression and survival rates for these patients indicates a substantial advantage, compared to historical controls, in terms of overall survival and distant metastasis-free survival. Clinical trial information: NCT01253096.
THE ASSOCIATION OF DEPRESSION AT ANY TIME TO THE RISK OF DEATH FOLLOWING CORONARY ARTERY DISEASE DIAGNOSIS: THE INTERMOUNTAIN INSPIRE REGISTRY
Authors: Heidi Thomas May, Benjamin Horne, Stacey Knight, Kirk Knowlton, Tami Bair, Donald Lappe, Viet Le, Joseph B. Muhlestein
Journal: Journal of the American College of Cardiology (2017)
DELETERIOUS MUTATIONS IN SCN10A ARE ASSOCIATED WITH LONG QT SYNDROME
Authors: Maen D. Abou Ziki, Sara Seidelmann, Emily Smith, Anand Narayanan, Gourg Atteya, Yuexin Jiang, Rodolfo Gil-Fernandez, Mark Marieb, Joseph Akar, Arya Mani
Journal: Journal of the American College of Cardiology (2017)
A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.
Authors: Andrea Borghese Apolo, Howard L. Parnes, Ravi Amrit Madan, James L. Gulley, John Joseph Wright, Kattie Khadar, Jane B. Trepel, Jeffrey Schlom, Philip M. Arlen, Maria Merino, Seth M. Steinberg, Peter L. Choyke, Maria Liza Lindenberg, Karen A. Kurdziel, Les Folio, William Douglas Figg, Piyush K. Agarwal, Donald P. Bottaro, William L. Dahut
Journal: Journal of Clinical Oncology (2013)

TPS4589 Background: Accumulating evidence supports MET as a therapeutic target in urothelial carcinoma. Activated MET can promote angiogenesis and tumor growth by upregulating VEGF and may play a role in urothelial carcinoma pathogenesis. Cabozantinib inhibits primarily VEGFR2 and MET pathways. Cabozantinib has been approved by the FDA for the treatment of progressive metastatic medullary thyroid cancer, is in Phase 3 trials for metastatic castration-resistant prostate cancer and has demonstrated clinical activity in multiple solid tumors. We previously reported that shed MET levels in serum and urine of patients with urothelial carcinoma correlate with stage, presence of visceral metastases and urinary source and that cabozantinib is effective in reversing HGF-driven urothelial carcinoma cell growth and invasion. These data support the evaluation of cabozantinib in patients with metastatic urothelial carcinoma. Methods: This is a phase II study of oral cabozantinib 60mg daily given continuously in 28-day cycles. There are three study cohorts: [1] metastatic urothelial carcinoma [2] bone only metastatic urothelial carcinoma [3] metastatic non-urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis. A maximum of 55 subjects will be enrolled. Up to 45 patients will be accrued to cohort 1.The remainder will be enrolled on exploratory cohorts 2 &amp; 3. A two-stage single-arm phase II design will be employed. The primary objective is to determine the objective response rate in patients with metastatic urothelial carcinoma who have progressed on prior chemotherapy. Secondary objectives include progression free survival, safety and toxicity, and overall survival. Exploratory objectives include tumor tissue Met expression, shed MET levels in serum and urine, immune subsets, genetic biomarkers, molecular markers of angiogenesis and circulating tumor cells, correlation with clinical response parameters. Finally we will explore treatment evaluation with FDG and NaF PET/CT compared to standard imaging. This study is supported by the Cancer Therapy Evaluation Program (CTEP). NCT01688999 Clinical trial information: NCT01688999.
Platelets From Sickle Cell Disease Individuals Induce Endothelial Activation, Demonstrating ICAM-1 and E-Selectin Adhesion Molecule Expression, Inflammatory Cytokine Production and Activation of NFκB Transcription Factor Gene Expression.
Authors: Renata Proença-Ferreira, Ana Flavia Brugnerotto, Vanessa Tonin Garrido, Marilene de Fatima Reis Ribeiro, Fabiola Traina, Sara T Olalla Saad, Fernando Ferreira Costa, Nicola Conran
Journal: Blood (2012)
SAFETY AND EFFICACY OF TRANSPEDAL ACCESS FOR THE MANAGEMENT OF COMPLEX PERIPHERAL ARTERIAL DISEASE
Authors: Konstantinos Marmagkiolis, Jihad Mustapha, Miguel Montero-Baker, Konstantinos Charitakis, Cezar Iliescu, Dmitriy Feldman, Mehmet Cilingiroglu
Journal: Journal of the American College of Cardiology (2017)
Mercury Spill Responses — Five States, 2012–2015
Authors: Ryan J. Wozniak, Anne E. Hirsch, Christina R. Bush, Stuart Schmitz, Jeff Wenzel
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Despite measures to educate the public about the dangers of elemental mercury, spills continue to occur in homes, schools, health care facilities, and other settings, endangering the public's health and requiring costly cleanup. Mercury is most efficiently absorbed by the lungs, and exposure to high levels of mercury vapor after a release can cause cough, sore throat, shortness of breath, nausea, vomiting, diarrhea, headaches, and visual disturbances (1). Children and fetuses are most susceptible to the adverse effects of mercury vapor exposure. Because their organ systems are still developing, children have increased respiratory rates, and they are closer to the ground where mercury vapors are most highly concentrated (2). To summarize key features of recent mercury spills and lessons learned, five state health departments involved in the cleanup (Iowa, Michigan, Missouri, North Carolina, and Wisconsin) compiled data from various sources on nonthermometer mercury spills from 2012 to 2015. The most common sites of contamination were residences, schools and school buses, health care facilities, and commercial and industrial facilities. Children aged <18 years were present in about one third of the spills, with approximately one in seven incidents resulting in symptoms consistent with acute mercury exposure. To protect the public's health after a mercury spill, it is important that local, state, and federal agencies communicate and coordinate effectively to ensure a quick response, and to minimize the spread of contamination. To reduce the number of mercury spills that occur in the United States, public health officials should increase awareness about exchange programs for mercury-containing items and educate school and health care workers about sources of mercury and how to dispose of them properly.
EDOXABAN THERAPY INCREASES TREATMENT SATISFACTION AND REDUCES UTILIZATION OF HEALTH CARE RESOURCES: AN ANALYSIS FROM THE EDOXABAN VERSUS WARFARIN IN SUBJECTS UNDERGOING CARDIOVERSION OF ATRIAL FIBRILLATION (ENSURE-AF) STUDY
Authors: Andreas Goette, Winghan Kwong, Michael Ezekowitz, Maciej Banach, Soren Hjortshoj, Dmitry Zamoryakhin, Gregory Lip
Journal: Journal of the American College of Cardiology (2017)
CARDIAC PLASTICITY PREDICTS OUTCOME AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE AORTIC STENOSIS
Authors: Kimi Sato, Arnav Kumar, Brandon Jones, Stephanie Mick, Amar Krishnaswamy, Richard Grimm, Milind Desai, Brian Griffin, L. Leonardo Rodriguez, Samir Kapadia, Zoran Popovic
Journal: Journal of the American College of Cardiology (2017)
Factors Associated With Being Unaware of Having Diabetes
Authors: Andy Menke, Sarah Casagrande, M. Larissa Avilés-Santa, Catherine C. Cowie
Journal: Diabetes Care (2017)

An improved understanding of which groups are more likely to be unaware of their diabetes may lead to more efficient screening, improved awareness, and overall better treatment for diabetes. Our objective was to investigate factors associated with being unaware of having diabetes among adults with diagnosed and undiagnosed diabetes.

The 2011–2014 National Health and Nutrition Examination Survey (NHANES) is a stratified, multistage probability survey representative of the civilian, noninstitutionalized U.S. population (1). Data were collected during an in-home interview and a visit to a mobile examination center. We used data from 1,879 participants with either diagnosed or undiagnosed diabetes (based on a single measurement of A1C, fasting plasma glucose, or 2-h plasma glucose).

Using logistic regression, we calculated odds ratios of being unaware of diabetes associated with age, race/ethnicity, sex, gestational diabetes mellitus (GDM), family history of diabetes, education, household income, smoking status, BMI, work-time activity, leisure-time activity, no health insurance, location of routine health …
Emergence of Long-Lived Autoreactive Plasma Cells in the Spleen of Primary Warm Auto-Immune Hemolytic Anemia Patients Treated with Rituximab
Authors: Matthieu Mahevas, Marc Michel, Benoit Vingert, Julien Moroch, David Boutboul, Sylvain Audia, Julie Ripa, Nicolas Cagnard, Karin Tarte, Simon le Gallou, Lan-huong Thai, France Noizat-Pirenne, Bertrand Godeau, Jean-Claude Weill, Claude-Agnès Reynaud
Journal: Blood (2014)
EVALUACIÓN DE LA CLASIFICACIÓN NICE (NBI INTERNATIONAL COLORRECTAL ENDOSCOPIC CLASSIFICATION) PARA PÓLIPOS SUBCENTIMÉTRICOS EN UNIDAD DE ENDOSCOPIA DIGESTIVA EN HOSPITAL DE TERCER NIVEL
Authors: J García Lledó, G Pérez, A Clemente, O Nogales Rincon, B Merino Rodriguez, L Perez, C Gonzalez Asanza
Journal: Endoscopy (2015)

Introducción: La clasificación NICE permite la diferenciación entre pólipos hiperplásicos y adenomatosos de colon.
INDEPENDENT PRE PROCEDURAL ECHOCARDIOGRAPHIC PREDICTORS OF MITRAL VALVE RESTENOSIS AFTER PERCUTANEOUS MITRAL BALLOON VALVULOPLASTY IN A LARGE CONSECUTIVE COHORT FOLLOWED UP TO TWO DECADES
Authors: Alfredo Ferreira Neto, Jose de Ribamar Costa, Auristela Ramos, Rafael Meneguz-Moreno, Sergio Braga, Dimytri Siqueira, Zilda Meneghelo, Nisia Gomes, Cesar Esteves, Mercedes Maldonado, Amanda Sousa, Alexandre Abizaid
Journal: Journal of the American College of Cardiology (2017)
SPONTANEOUS CORONARY ARTERY DISSECTION IN A TRANSPLANTED HEART
Authors: Sohaib Tariq, Roshni Narurkar, Anoshia Raza, Srikanth Yandrapalli, Mina'a Shahid, Wilbert Aronow, Ali Ahmed, Howard Cooper, Julio Panza, Alan Gass
Journal: Journal of the American College of Cardiology (2017)
NICE recommends ixekizumab for persistent severe plaque psoriasis
Authors: Susan Mayor
Journal: BMJ (2017)

The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.

The guidance recommended ixekizumab as an option for treating plaque psoriasis in adults, but only if they had severe disease (a …
Is there any difference in overall response rate according to kras mutation in advanced colorectal cancer (aCRC)?
Authors: José Antonio Rivadeneira Cabana, Antonio Viudez, David Guerrero, Irene Hernandez, Maria Luisa Gomez Dorronsoro, Marta Montes, Juan Verdun, Antonio Tarifa, Javier Suarez, Angela Fernandez de Lascoiti, Miguel Angel Ciga Lozano, Ruth Vera
Journal: Journal of Clinical Oncology (2013)

e14589 Background: Tejpar et al (JCO2012; 30(29):3570-7) showed that patients with aCRC and Gly13D kras mutation experienced worse response rate with chemotherapy alone compared to those with other kras mutations. This retrospective study analyzes differences in clinical and radiological response between patients with the two main kras mutations: Gly12Val or Gly13D. Methods: In this retrospective-observational trial, patients with aCRC and Gly12Val and Gly13D kras mutation tumours participated. Clinical and radiological responses of patients with each of the two kras mutation, detected by Therascreen technique and treated with conventional first-line chemotherapy schemes, were recorded. SPSSv17 was employed. ORR (Overall Response Rate: CR+PR) and OCR (Overall Control Rate: CR+PR+SD) were calculated. Results: From November 2005 to October 2012, 51 patients with aCRC and Gly12Val or Gly13D kras mutations were included. Median age was 66 (41-80); 52.7 % men and 49.1% with synchronous disease. Kras mutation status was: 47.3% Gly13D and 52.7% Gly12Val. The chemotherapy schedules were based on Oxaliplatin, Irinotecan and others (61.5%, 25% and 13.5% respectively). While ORR was observed in 39.22 % (38.46 % Gly12Val and 40% Gly13D; p: 0.57), OCR was 76.5% (76.9% Gly12Val and 76% Gly13D; p: 0.60). In the Kaplan-Meier analysis, OS showed no difference between both kras mutation groups (Gly12Val: 29 months; Gly13D: 28 months; p: 0.28). Conclusions: According to our results, and in contrast to other studies outcomes, there is no difference regarding ORR, OCR or OS in patients with both different kras mutation: Gly12Val or Gly13D; however, the hypothetical role of Gly13D mutation as a biomarker of chemotherapy resistance, should be evaluated in prospective studies.
FV-HSP70 PROTECTS MYOCARDIUM FROM ISCHEMIC/REPERFUSION INJURY
Authors: Takehiro Nakahara, Takashi Tanimoto, Missag H. Parseghian, Hideki Kawai, Navneet Narula, Dongbin Kim, Robert Nishimura, Richard H. Weisbart, Grace Chan, Richard A. Richieri, Nezam Haider, Glenn T. Reynolds, John Billimek, Francis G. Blankenberg, Artiom D. Petrov, Partho Sengupta, Takashi Akasaka, Harry Strauss, Jagat Narula
Journal: Journal of the American College of Cardiology (2017)
IVABRADINE IN PATIENTS WITH SYMPTOMATIC INAPPRIOPRATE SINUS TACHYCARDIA: LONG-TERM OBSERVATIONAL STUDY
Authors: Pawel Ptaszynski, Krzysztof Kaczmarek, Iwona Cygankiewicz, Thomas Klingenheben, Irmina Urbanek, Jerzy K. Wranicz
Journal: Journal of the American College of Cardiology (2017)
PERCUTANEOUS PATENT FORAMEN OVALE CLOSURE BENEFIT: IS RIGHT PATIENT SELECTION THE ANSWER?
Authors: Luis Almeida-Morais, Lidia Sousa, Antonio Fiarresga, Ana T. Timoteo, Jose Diogo Martins, Filipa Ferreira, Jose Alberto Oliveira, Cristina Soares, Ana Agapito, Fatima Pinto, Rui Ferreira
Journal: Journal of the American College of Cardiology (2017)
The safety profile of eltrombopag, a novel oral platelet growth factor, in thrombocytopenic patients and healthy subjects
Authors: D. Provan, M. Saleh, S. Goodison, R. Rafi, N. Stone, J. M. Hamilton, H. Hassani, B. Mayer, J. Uhl, J. Jenkins
Journal: Journal of Clinical Oncology (2006)

18596 Background: Eltrombopag (SB-497115) is an oral, non-peptide, small molecule, thrombopoietin receptor agonist being tested as a potential treatment for thrombocytopenia. Eltrombopag has been shown to increase platelet counts in both healthy subjects and thrombocytopenic patients. Methods: Safety and tolerability data for eltrombopag (3–75 mg for up to 6 weeks) is presented from randomized, placebo-controlled, parallel group clinical trials involving 115 healthy subjects and 104 immune thrombocytopenic purpura (ITP) patients. Safety and tolerability endpoints involved assessment of adverse events (AE) and clinical laboratory parameters, including ECGs and platelet function. Results: In 3 Phase I trials, 98 healthy males received active eltrombopag QD for up to 10 days at 3–75 mg. In the Phase II dose ranging study, 78 chronic ITP patients (28 male/50 female) received active eltrombopag QD for 6 weeks at doses of 30–75 mg. There was no apparent relationship between active and control arms, the dose of eltrombopag and the incidence or severity of AEs, changes in laboratory values, platelet function or cardiac parameters in any of the studies. There were no serious adverse events (SAEs) reported by subjects in the 3 Phase I studies. 5 SAEs were reported in 1 patient in the ITP study that were considered by the investigator as possibly associated with administration of 50 mg eltrombopag. No SAEs were related to 30 mg or 75 mg eltrombopag, and 2 SAEs in 2 patients were related to placebo. Conclusions: There was no apparent relationship between eltrombopag dose and safety endpoints in these studies. These encouraging safety and tolerability data support the further testing of eltrombopag in phase II and III studies involving patients with ITP and chronic liver disease, and cancer patients receiving thrombocytopenic chemotherapy. [Table: see text]